Our indicative theme of Gene Modifying shares is down by about 24% year-to-date, in comparison with the S&P 500 which has remained nearly flat over the identical interval. The latest sell-off comes on the again of rising bond yields, which have induced buyers to rotate out of know-how a www.nasdaq.com
Our indicative theme of Gene Modifying shares is down by about 24% year-to-date, in comparison with the S&P 500 which has remained nearly flat over the identical interval. The latest sell-off comes on the again of rising bond yields, which have induced buyers to rotate out of know-how a
www.nasdaq.com